d-Amphetamine Patch Cuts SKAMP Scores Across Pediatric ADHD Subgroups
This preplanned subgroup analysis of a crossover trial shows how a 9-hour dextroamphetamine transdermal system performs by dose, sex, ADHD presentation, and baseline severity, informing pharmacists who counsel on non-oral stimulant options in children and adolescents.
📅 Journal publication: Oct 2024(online Jan 10, 2025)·Last updated: Nov 15, 2026
Could d-ATS be the new alternative for pediatric ADHD management?
The study explores an alternative ADHD treatment for children and adolescents, assessing a new transdermal system. d-Amphetamine transdermal system (d-ATS) showed significant improvement in the SKAMP total score compared to placebo, with scores ranging from -4.5 to -7.6 depending on dosage. d-ATS could provide a new viable option for ADHD management in children and adolescents, although tolerability issues like irritability and appetite loss were noted. d-ATS shows promise as an effective treatment for ADHD in the pediatric population.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Cutler AJ, Komaroff M, Castelli M, Meeves S, Balakrishnan K, Khan M
Citation:Cutler AJ, Komaroff M, Castelli M, et al. d-Amphetamine Transdermal System (d-ATS) in Treatment of Children and Adolescents With ADHD: SKAMP Score Analysis From a Pivotal Trial. CNS spectrums. 2024;29(5):502. doi:10.1017/S1092852924001664